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against three different strains of Streptococcus pneumoniae (Penicillin-susceptible, Penicillin-intermediate and
Penicillin-resistant) are studied.
Results: These properties were analyzed based on the measurement of the inhibition zone, minimum inhibitory
concentration (MIC), and rate of kill revealed that curcuminmonoglucoside, curcumin diglucoside and curcumin
possessed strong antimicrobial properties even on the Penicillin-resistant strains. Additionally, the molecular
docking simulation analyses against Penicillin Binding Protein of S. pneumoniae also conﬁrm that these
compounds docked at the active site of the enzyme. Further, the molecular dynamics simulation validates the
conformational stability of the docked ligand–protein complexes in the dynamic environment.
Conclusion: curcumin monoglucoside, curcumin diglucoside and curcumin can be prescribed for treatment
against Penicillin-resistant S. pneumoniae.
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Streptococcus pneumoniae is a Gram-positive, alpha-hemolytic
and facultative anaerobic bacterium which belongs to Streptococcus
genus [1]. The bacterium is usually present in the human's upper
respiratory tract. It is considered as one of the human pathogens for
severe infections causing life threatening diseases such as pneumonia,
meningitis and sepsis among infants and young children [2,3]. In the
recent years, there has been an alarming rise in antibiotic-resistant
S. pneumoniae strains which has lead to a major concern. Also, the
emergence of multi drug resistant strain against the commonly used
antibiotics has been observed in several cases. Hence, there is a
necessity for developing a novel antibiotic or novel drug or a vaccine.
Also, the limitations of recently developed vaccines (protein-capsular
polysaccharide conjugate) have kept no choice for the researchers and
the scientiﬁc community to focus on the developing new therapeutics
or novel drug for the anti-biotic resistant S. pneumoniae strains [4,5,6].
In the recent year's curcumin, a principal component of turmeric
(Curcuma longa) and their derivatives has been widely studied
because of their potential activity against many diseases such asZhang).
idad Católica de Valparaíso.
araíso. Production and hosting by Elcancer, Alzheimer's disease, anti inﬂammatory etc [7,8,9,10]. There are
also reports of curcumin possessing anti microbial property [11] which
gained our attention on investigating the antimicrobial property
of curcumin and its derivatives against three different strains of
S. pneumoniae. In the present investigation, the antimicrobial activity
of these compounds was evaluated against Penicillin-susceptible,
Penicillin-intermediate and Penicillin-resistant strains of S. pneumoniae
by estimating the zone of inhibition of the bacterial growth, Minimum
Inhibitory Concentration (MIC) and rate of kill. Furthermore, a
molecular docking simulation analysis was performed for curcumin
and its derivatives against the Penicillin Binding Protein (PBP) of
S. pneumoniae to understand the molecular interaction and binding
mode of the docked compounds at the active site of the enzyme. The
PBP of S. pneumoniae are known to involve in the ﬁnal stages of
the peptidoglycan synthesis, which is a major component of bacterial
cell walls and essential for bacterial growth and cell division.
Thus, Inhibition of PBPs will lead to the irregularities in cell wall
structure such as elongation, lesions, loss of selective permeability,
and eventual cell death and lysis. Moreover, there are reports of
curcumin inhibiting the PBP of certain bacterial species. This enzyme
has a penicillin-insensitive trans glycosylase N-terminal domain
which is involved in the formation of linear glycan strands and a
penicillin-sensitive transpeptidase C-terminal domain involved in cross
linking of the peptide subunits [12,13,14]. Furthermore, the docked
compounds from the molecular docking result were validated bysevier B.V. All rights reserved.
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5.0 [15].
2. Materials and method
2.1. Pathogens
Three S. pneumoniae strains used in the present study are the
clinical isolates from three different patients of the Department of
Respiratory Medicine, Zhangqiu Hospital of Traditional Chinese
Medicine, Zhangqiu, 250200, Shandong, China. The descriptions of the
strains used in the present study are described in Table 1 below.
2.2. Chemicals
Curcumin and its derivatives curcumin monoglucoside,
curcumin diglucoside, hexahydrocurcumin, tetrahydrocurcumin,
bisdemethoxycurcumin and demethoxycurcumin along with
Penicillin G were purchased from ABI Chem, Germany (Table 6).
2.3. Anti-microbial activity
In the present investigation, curcumin and its derivatives were used
to check the bacterial growth inhibitory potencywhichwas determined
by susceptibility test using the Kirby–Bauer disk following the protocol
developed by Bauer et al. [16,17], and Pathak et al. [18], with slight
modiﬁcations.
Initially, the samples were infused with a ﬁlter paper having a
concentration of 250 μg/disk. The disks were then placed on the
Mueller–Hinton agar (MHA) plates which were seeded with the target
test strains. Penicillin G was used as a positive control. The plates were
then kept for incubation at 37°C overnight. After incubation, the zone
of inhibition was measured using an antibiotic zone scale. All the
experiments were carried out in duplicates.
Further, the quantitative evaluation of the antibacterial activity of
curcumin and its derivatives was estimated by MIC of these
compounds based on the serial dilution method using micro-well
following the protocol developed by Bauer et al. [16,17], and Pathak et
al. [18], with slight modiﬁcations. The S. pneumoniae strains which
were cultured in nutrient broth at 37°C overnight were used as the
inoculums for estimating the MIC. The wells of the ﬂat bottom 96 well
culture plates were diluted with curcumin and its derivatives with
different concentrations ranging from 0.0003–2 mg/mL. The wells
were then treated with nutrient broth inoculums of the three
S. pneumoniae strains for around 40–60 μL which was then incubated
for overnight at 37°C along with Penicillin G as the positive control
and the absorbance was measured at 600 nm.
2.4. Determination of rate of kill
This assay was performed to evaluate the rate of killing
S. pneumoniae strains by the compounds following the protocol
described by Eliopoulos [19] and Cruishank et al. [20]. The compounds
were then loaded with McCartney bottles with 10 mL of Mueller
Hinton broth at 1× MIC and 2× MIC. The inoculums density having
95 cfu/mL, approximately was further veriﬁed by total viable count,
and 10 mL volumes of the inoculate bottles. The bottles were then
incubated on an orbital shaker at 37°C at 120 RPM. Finally, 100 μLTable 1
S. pneumoniae used in the present study.
SN Strain name Penicillin resistance
1 SPCH-02 Susceptible
2 SPCH-24 Intermediate
3 SPCH-45 Resistantof the aliquot was removed from the culture medium at 5 h and 10 h
for the determining the cfu/mL by the plate count technique [21] by
plating out 25 μL of the dilutions. The emergent bacterial colonies
were counted after incubating at 37°C for 24 h and its cfu/mL was
calculated.
2.5. Molecular docking simulation
In the present study, the author's have also performed molecular
docking simulation studies of curcumin and its derivatives along with
Penicillin G against S. pneumoniae PBP to understand the molecular
interaction analysis of these compounds and its binding site. For
these purposes, the two dimensional structure of curcumin and its
derivatives along with Penicillin G was downloaded from the National
Center for Biotechnology Information PubChem database [22].
The two dimensional structures were then converted into three
dimensional format (sybyl moL2) using ChemOfﬁce 2010 (ChemOfﬁce
2010, CambridgeSoft Corporation, Cambridge, MA, USA) (Table 5).
On the other hand, the X-ray crystal structure of S. pneumoniae PBP
(PDB ID: 2XD5) was downloaded from the RCSB Protein Data Bank
(http://www.rcsb.org/). The potential ligand binding site of the PBP
enzyme was predicted using Molegro Virtual Docker 5.0 [23] and the
binding site has a volume of 233.984 A3 and a surface area of 701.44
A2. Also, the binding site was set inside a restricted sphere of X: 38.16,
Y: 22.31, Z: 62.03 having a radius 14 A with a grid resolution of 0.30 A.
For the molecular docking purposes, the compounds were then loaded
in Molegro Virtual Docker 5.0 and its bond ﬂexibility was set along
with the side chains of the amino acid which were also set inside the
restricted sphere. The ﬂexibility was set with a tolerance of 1.10 and
strength of 0.90. The RMSD threshold for the multiple cluster poses
was set at 2.00 A with 100.00 energy penalty values. The docking
algorithm was set for a maximum of 1500 iteration with a simplex
evolution size of 50. The docking simulation was run for at least 50
times for 10 poses and the best poses were selected based on the
scoring function such as the Rerank score, Moldock score and
interaction energy [24].
2.6. MD simulation
The 2XD5 enzyme and the protein-ligand complexes viz.
2XD5-curcumin diglucoside, 2XD5-curcumin monoglucoside,
2XD5-curcumin complexes and 2XD5-Penicillin complex (control)
were carried out for a molecular dynamics simulation. Initially, the
system of 2XD5 and 2XD5-ligand complexes was minimized using
steepest descent energy minimization and equilibrated for at least
100 ps with NVT (Canonical) and NPT (Isothermal-isobaric) ensemble
equilibration for 5000 steps. Finally, the equilibrated systems were
subjected to 20 ns MD simulation production. The trajectory ﬁle
was processed and the RMSD graph was plotted for 2XD5-and the
2XD5-ligand complexes. All simulations were performed in Ubuntu
Linux 14.0 LTS with intel i5 processor using GROMACS 5.0 with
GROMOS96 43a1 force ﬁelds [15].
3. Results
The antimicrobial screening carried out against the S. pneumoniae
strains revealed curcumin monoglucoside, curcumin diglucoside and
curcumin exhibit a strong anti microbial property against all the three
S. pneumoniae strains. The zones of inhibition of these compounds
were found in more than that of Penicillin G (control) which is
shown in Table 2. The zone of inhibition of these compounds was
more than 20 mm in the Penicillin-resistant S. pneumoniae strain.
On the other hand, bisdemethoxycurcumin, demethoxycurcumin
and tetrahydrocurcumin showed no zone of inhibition in the
Penicillin-resistant strain. These three compounds also developed
a zone of inhibition, which is less than the threshold value of
Table 2
Zone of inhibition and MIC values of Curcumin and its derivatives against Penicillin-Susceptible, Penicillin-Intermediate and Penicillin-Resistant strains of S. pneumoniae.
SN Compound Penicillin-susceptible Penicillin-intermediate Penicillin-resistant
ZI (mm) 250 μg/ml MIC (μg/mL) ZI (mm) 250 μg/mL MIC (μg/mL) ZI (mm) 250 μg/mL MIC (μg/mL)
1 Bisdemethoxycurcumin 15 200 13 200 13 200
2 Curcumin 20 10 20 15 N20 N15
3 Curcumin diglucoside 22 7 24 10 N20 10
4 Curcumin monoglucoside 25 5 25 5 N20 10
5 Demethoxycurcumin – 100 – 100 – N100
6 Hexahydrocurcumin – 200 – 200 – 200
7 Penicillin G (control) 18 15 15 20 – N50
8 Tetrahydrocurcumin 10 80 – 80 – 80
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inactive.
Furthermore, to understand the factors which affect the
microbial growth inhibition of the S. pneumoniae strains the MIC
was evaluated against curcumin and its derivatives (shown in
Table 2). Curcumin monoglucoside exhibited an MIC of 5 μg/mL
each for Penicillin-susceptible and Penicillin-intermediate strains
and 10 μg/mL for Penicillin-resistant strain. Curcumin diglucoside
and curcumin also exhibited an MIC of 10 μg/mL and N15 μg/mL
against the Penicillin-resistant strain. While the MIC values of
bisdemethoxycurcumin and hexahydrocurcumin was more than 200
in the Penicillin-resistant strain (Table 2). Also, the results of time kill
studies are presented in Table 3. The data are presented in terms of
the Log10 cfu/mL which are based on the conventional bactericidal
activity standard and greater reduction in the viable colony count.
From the molecular docking simulation studies of curcumin and its
derivatives against PBP (PDB ID: 2XD5) of S. pneumoniae, it is revealed
that curcumin diglucoside, curcumin monoglucoside, and curcumin
docked at the active site of the PBP enzyme of S. pneumoniae with a
favorable Rerank score and docking score compared to Penicillin G
(Table 3). The docking result also correlated with the MIC values and
zone of inhibition values of these compounds and the details of
the ligand–protein interaction analysis are shown in Table 4. The
interacting atoms of the amino acid residues and ligand atoms along
with their interaction energy and interaction distances are measured
and shown in Table 4. Also, Fig. 2, Fig. 3, and Fig. 4 depict the binding
mode and electrostatic interaction map of these docked compounds at
the binding cavity of PBP.
Further, the result of trajectory analysis of the RMSD backbone of
2XD5, 2XD5–curcumin diglucoside, 2XD5–curcumin monoglucoside,
2XD5–curcumin and 2XD5–Penicillin complexes is plotted in a graph
(shown in Fig. 1). The conformational stability of the 2XD5 and 2XD5–
ligand complexes in the dynamic behavior is represented in the graph.
4. Discussion and conclusion
From Table 2, it is inferred that curcumin monoglucoside and
curcumin diglucoside possessed excellent activity in all the threeTable 3
Time kill assessment study of curcumin and its derivatives.
SN Compound Penicillin-susceptible P
Log10 Kill MIC Log10 Kill 2× MIC L
5 h 10 h 5 h 10 h 5
1 Bisdemethoxycurcumin 1.12 0.92 -0.52 -2.12 1
2 Curcumin 1.38 0.88 -0.32 -1.12 1
3 Curcumin diglucoside 1.12 0.92 -0.26 -2.91 1
4 Curcumin monoglucoside 0.92 0.77 -0.18 -2.54 1
5 Demethoxycurcumin 1.91 0.98 -0.53 -2.27 1
6 Hexahydrocurcumin 1.21 0.91 -0.51 -2.16 1
7 Tetrahydrocurcumin 1.07 0.98 -0.61 -2.97 1
8 Penicillin G (Control) 1.25 1.02 -0.43 -2.31 1strains of S. pneumoniae (Penicillin-susceptible, intermediate and
resistant) strains developing the maximum zone of inhibition,
which is shown in Table 2. Moreover, their zone of inhibition was
more than 12 mm which are the threshold value to be considered
as an active compound. Curcumin also possessed good activity with
a zone of inhibition of 20 mm in all the three S. pneumoniae strains
(Table 2). Meanwhile, Penicillin G (control) showed activity in
Penicillin-susceptible and intermediate strains with negative or no
activity in the Penicillin-resistant strain.
On the other hand, no zone of inhibition or no activity was observed
in demethoxycurcumin, hexahydrocurcumin and tetrahydrocurcumin
in the Intermediate and Resistant strains. While the bacterial
growth diameter was 16 mm, 14 mm and 13 mm respectively in
the case of Penicillin susceptible strain for demethoxycurcumin,
hexahydrocurcumin and tetrahydrocurcumin.
Again from theMIC assay, themaximumzoneof inhibition exhibited
anMIC of 5 μg/mL for susceptible and intermediate strains and 10 μg/mL
against resistant strains. Meanwhile, curcumin diglucoside inhibited the
bacterial growth at a 7 μg/mL for the susceptible strain and 10 μg/mL
each for the intermediate and resistant strain (Table 2). Curcumin
also exhibited an MIC of 10 μg/mL, 15 μg/mL and N15 μg/mL for
the susceptible, intermediate and resistant strains respectively.
Meanwhile Penicillin G (Control) has an MIC of 15 μg/mL for the
susceptible, and intermediate strain and N50 for the resistant strain.
Overall, curcumin monoglucoside, which exhibits the maximum zone
of inhibition, possessed the lowest MIC value for all the three strains.
In addition, the MIC values of curcumin were found to be 17 μg/mL,
12 μg/mL, and 21 μg/mL against Pseudomonas aeruginosa, Bacillus
subtilis, and Klebsiella pneumonia, respectively as reported by Gunes et
al. [25]. There are also reports on the derivatives of curcumin
possessing more potent antibacterial and antifungal activities than
curcumin as described by Chun et al [26]. Also, Sahu et al. [11]
reported the derivatives of curcumin also used as antibacterial
showed maximum activity against S. aureus and P. aeruginosa. Thus,
conﬁrming that derivatives possessed more powerful anti-bacterial
activity compared to curcumin.
Finally, from the antimicrobial activity screening results, it could be
inferred that curcumin monoglucoside, curcumin diglucoside andenicillin-intermediate Penicillin-resistant
og10 Kill MIC Log10 Kill 2×MIC Log10 Kill MIC Log10 Kill 2× MIC
h 10 h 5 h 10 h 5 h 10 h 5 h 10 h
.99 1.21 -0.72 -1.13 1.87 1.18 -0.79 -1.56
.82 1.01 -0.61 -1.14 1.91 1.21 -0.82 -1.36
.14 0.98 -0.56 -1.19 1.83 0.92 -0.96 -1.69
.55 1.01 -0.62 -1.95 1.72 1.21 -0.99 -1.41
.96 1.21 -0.45 -1.91 1.95 1.18 -0.84 -1.81
.92 1.12 -0.73 -1.78 1.76 1.28 -0.78 -1.62
.74 1.09 -0.81 -1.92 1.84 1.23 -0.84 -1.77
.95 1.02 -0.62 -1.32 1.98 1.2 -0.79 -1.69
Table 4
Docking scores of curcumin and its derivatives with Penicillin G as the control.
Name MolDock
scorea
Rerank
scoreb
Interactionc HBondd
Curcumin diglucoside -152.33 -138.77 -202.30 -13.12
Curcumin monoglucoside -163.70 -137.54 -195.45 -12.27
Curcumin -150.47 -127.34 -166.04 -9.06
Penicillin G (control) -135.95 -112.73 -139.09 -12.76
Tetrahydrocurcumin -133.56 -109.20 -156.67 -7.92
Demethoxycurcumin -140.25 -109.18 -144.44 -11.69
Bisdemethoxycurcumin -128.71 -106.83 -145.07 -5.51
Hexahydrocurcumin -127.10 -104.12 -142.80 -9.65
a Moldock score is derived from the PLP scoring functions with a new hydrogen bonding
term and new charge schemes [18].
b The rerank score is a linear combination of E-inter (Van der Waals, steric, hydrogen
bonding, electrostatic) between the ligand and the protein, and E-intra. (Van der Waals,
hydrogen bonding, torsion, sp2–sp2, electrostatic) of the ligand weighted by pre-deﬁned
coefﬁcients [18].
c The total interaction energy between the pose and the protein (kJ moL-1).
d Hydrogen bonding energy (kJ moL-1).
Table 6
Structures.
SN Compound Structures
1 Bisdemethoxycurcumin
2 Curcumin
3 Curcumin diglucoside
4 Curcumin monoglucoside
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intermediate and resistant strains of S. pneumonia.
Furthermore, the average log reduction in viable cell count in
time-kill assay ranges between -0.99 Log10 to -1.41 cfu/mL for
curcumin diglucoside against the Penicillin-resistant strains after 10 h
of interaction in 2× MIC. While curcumin monoglucoside ranges
between -0.96 Log10 to -1.69 cfu/mL which conﬁrm the validity of
these derivatives acted upon the Penicillin-resistant strains (Table 3).
Additionally, the molecular docking simulation studies of curcumin
and its derivatives against PBP (PDB ID: 2XD5) also conﬁrmed the
effectiveness and inhibitory property of curcumin monoglucoside,
curcumin diglucoside and curcumin. The molecular docking result of
these tested compounds is shown in Table 3 where the strength of theTable 5
Molecular interaction analysis.
Compound Interaction Interaction
energy
Interaction
distance (Å)
Curcumin diglucoside Gln687(OE1)—O(3) -2.5 2.94
Asn656(O)—O(10) -1.92 3.22
Asn656(OD1)—O(10) -0.04 2.65
Asn656(ND2)—O(10) -2.24 2.85
Asn656(ND2)—O(0) -1.83 3.23
Ser457(OG)—O(6) -2.1 2.72
Gly559(N)—O(8) -2.5 3.25
Gly557(O)—O(8) -2.1 3.38
Ser460(OG)—O(14) -1.4 3.30
Asn518(ND2)—O(16) -1.67 2.64
Curcumin monoglucoside Gln687(N)—O(1) -2.5 2.63
Tyr690(N)—O(2) -0.89 3.30
Gln686(O)—O(2) -2.1 2.68
Ser460(OG)—O(7) -1.73 3.47
Lys463(NZ)—O(7) -1.89 3.50
Asn518(OD1)—O(7) -1.5 3.05
Ser460(N)—O(7) -0.70 3.32
Asn518(ND2)—O(10) -1.23 3.04
Thr654(OG1)—O(4) -2.5 2.81
Thr652(OG1)—O(6) -2.14 3.00
Val628(O)—O(5) -2.47 2.63
Curcumin Met556(O)—O(2) -1.5 3.13
Asn656(N)—O(0) -2.18 3.05
Ser460(OG)—O(4) -0.78 2.90
Thr654(N)—O(4) -2.31 2.86
Thr654(OG1)—O(4) -2.11 3.47
Ser516(OG)—O(5) -0.94 3.13
Asn656(N)—O(0) -2.18 3.05
Ser460(OG)—O(4) -0.78 2.90
Thr652(OG1)—O(5) -2.5 2.98
Gln686(O)—O(3) -1.76 3.11
Gln686(OE1)—O(3) -2.1 3.13
5 Demethoxycurcumin
6 Hexahydrocurcumin
7 Tetrahydrocurcuminligand–protein interaction is considered based on the Rerank score,
which is deﬁned as a linear combination of E-inter which is of Van
der Waals, steric, electrostatic, hydrogen bonding, energy between
Fig. 1. RMSD backbone of 4XD5, 4XD5–curcumin diglucoside complex, 4XD5–curcumin
monoglucoside complex, 4XD5–curcumin complex and 4XD5–penicillin G complex.
Fig. 2. a: Ligand–protein molecular interaction illustrating the binding mode of curcumin
diglucoside (yellow color) at the binding cavity of PBP (PDB ID: 2XD5); b: Electrostatic
interactions map of curcumin diglucoside (yellow color) at the binding cavity of PBP.
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hydrogen bonding, torsion, electrostatic, sp2–sp2 energy of the ligand
weighted by pre-deﬁned coefﬁcients [18]. From the docking result,
curcumin diglucoside, curcumin monoglucoside, and curcumin formed
bonds and non-bond interaction at the binding cavity of the PBP as
evident from the interaction energy and hydrogen bonding energy
(Table 4).
Moreover, the zone of inhibition values and MIC values
corresponds with the docking scores of curcumin diglucoside,
curcumin monoglucoside, and curcumin (Table 4). These compounds
docked at the binding cavity with a Rerank score of -138.77 kJ moL-1,
-137.54 kJ moL-1 and -127.34 kJ moL-1 respectively.
Furthermore, to comprehend the deepness of the ligand-protein
molecular interaction, the ligand energy inspector was employed for
analyzing the ligand–protein interaction. The ligand–protein interaction
analysis for curcumin diglucoside, curcumin monoglucoside and
curcumin, which represents the interacting residues, interaction energy
and interaction distances are shown in Table 4. The snapshots of the
ligand–protein molecular interaction illustrating the binding mode of
these compounds at the binding cavity of PBP and their electrostatic
interaction map are shown in Fig. 2, Fig. 3, and Fig. 4 respectively.
Curcumin diglucoside formed molecular interaction with Ser457,
Ser460, Asn518, Gly557, Gly559, Asn656 and Gln687 (Fig. 2);
curcumin monoglucoside formed molecular interaction with Ser460,Fig. 3. a: Ligand–protein molecular interaction illustrating the binding mode of curcumin
monoglucoside (yellow color) at the binding cavity of PBP (PDB ID: 2XD5); b: Electrostatic
interactions map of curcumin monoglucoside (yellow color) at the binding cavity of PBP.
Fig. 4. a: Ligand–protein molecular interaction illustrating the binding mode of curcumin
diglucoside; b: electrostatic interactions map of curcumin (yellow color) at the binding
cavity of PBP.
13L.-M. Li et al. / Electronic Journal of Biotechnology 19 (2016) 8–14Lys463, Asn518, Val628, Thr652, Thr654, Gln686, Gln687 and Tyr690
(Fig. 3), and curcumin formed molecular interaction with Ser460,
Ser516, Met556, Thr652, Thr654, Asn656 and Gln686 (Fig. 4).
Lastly, from the molecular dynamics simulation analysis, the
backbone root mean square deviation (RMSD) values of protein and
the protein-ligand complex during 20 ns of MD simulations (Fig. 1),
indicates the RMSD values for 2XD5-Monoglucoside ligand complex is
more stable than 2XD5 and 2XD5-Penicillin G complex, indicating the
conformational ﬂexibility in the dynamic behavior.
To conclude, curcumin and its derivatives were evaluated
for there antimicrobial property against Penicillin-susceptible,
Penicillin-intermediate and Penicillin-resistant strains of S. pneumoniae
where three derivatives possessed strong anti microbial property
against all the three strains based on the diameter of the zone o
inhibition and MIC values. The compounds were further screened for
molecular docking simulation against the Penicillin Bonding protein
(PDB ID: 2XD5) where the compounds exhibit favorable docking score
compared to Penicillin G (Positive Control).
Again, from the 20 ns molecular dynamics simulation revealed that
the 2XD5–curcumin diglucoside, 2XD5–curcumin monoglucoside and
2XD5–curcumin docked complexes showed stable RMSD backbone in
the dynamic behavior. Hence, the authors conclude that curcumin andits derivatives curcumin diglucoside and curcumin monoglucoside can
be prescribed in treating in Penicillin-Resistant strains of S. pneumoniae.
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